RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT. A live audio webcast of the call will b ...

ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the Stocks That Could Mint Millionaires in 2026. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance ADMA Biologics, Inc. (NASDAQ:ADMA) markets BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeli ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $134.2 million, reflecting a 10% increase quarter-over-quarter and a 12% increase year-over-year [5][11] - GAAP net income reached $36.4 million, up 6% quarter-over-quarter and 1% year-over-year [5][11] - Adjusted EBITDA grew to $58.7 million, representing a 16% quarter-over-quarter increase and a 29% year-over-year increase [5][11] Business Line Data and Key Metrics Changes - ASCENIV, the company's specialty immunoglobulin product, showed record utilization driven by strong prescriber adoption and sustained patient demand [6][10] - Product-level gross margins reached 63.7% during Q3 2025, excluding a plasma sale of $13.8 million [11][12] - The company completed a sale of approximately $13.8 million of normal-source plasma at a negative margin contribution to optimize working capital [13] Market Data and Key Metrics Changes - The company anticipates improved ASCENIV reimbursement access beginning in 2026, with payer negotiations progressing positively [6][10] - A retrospective cohort analysis showed a significant reduction in infection rates for patients switching from standard IG therapy to ASCENIV, with a reduction of over 50% [7][26] Company Strategy and Development Direction - The company aims to expand ASCENIV access and utilization, scale yield-enhanced production, and drive continued margin expansion [10][19] - The SG-001 program is progressing, with potential to address significant unmet medical needs and expected to contribute to long-term revenue growth [9][19] - The company maintains a disciplined capital allocation strategy, focusing on stockholder value through share repurchases and reinvestment in growth initiatives [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $1.1 billion in annual revenue by 2029, supported by yield-enhancement efficiencies and expanding ASCENIV demand [14][15] - The company expects continued strong double-digit revenue growth into 2026, driven by improved payer access and increased utilization of ASCENIV [17][31] Other Important Information - The company maintains a strong balance sheet with an undrawn $225 million revolving credit facility, providing flexibility for growth initiatives [10][14] - The FDA's release of yield-enhanced production batches is expected to improve gross margins starting in Q4 2025 [8][52] Q&A Session Summary Question: Can you provide details on the publication of ASCENIV data? - Management confirmed plans for a peer-reviewed publication in early 2026, highlighting significant infection reduction data [24][26] Question: What is the expected impact of ASCENIV data on demand? - Management anticipates that the data will reinforce prescriber confidence and potentially lead to earlier use of ASCENIV in treatment cycles [29][31] Question: What factors contributed to raising revenue guidance? - Management cited record product pull-through and increased availability of ASCENIV as key factors for confidence in raised guidance [35][36] Question: Are there any gating factors for yield-enhanced product impact in Q4? - Management indicated that yield-enhanced products will flow through product sales in Q4 without significant gating factors [41] Question: How will gross margins expand in the coming quarters? - Management expects gross margins to potentially exceed 70% in 2026 due to ongoing yield enhancements and product mix shifts [52] Question: What is the status of payer negotiations for ASCENIV? - Management reported positive negotiations with payers, with expectations for improved access and reduced restrictions in 2026 [54][58] Question: How many physicians or centers are currently using ASCENIV? - Management noted that there are over 100 prescribing physicians, with a target of reaching around 300 to support revenue goals [60][62] Question: Can the hit rate for plasma collections improve over time? - Management expressed optimism that the amount of high-titer plasma collected will grow, supported by strong relationships with third-party suppliers [68]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $134.2 million, reflecting a 10% increase quarter-over-quarter and a 12% increase year-over-year [5][11] - GAAP net income reached $36.4 million, up 6% quarter-over-quarter and 1% year-over-year [5][11] - Adjusted EBITDA grew to $58.7 million, representing a 16% quarter-over-quarter increase and a 29% year-over-year increase [5][11] Business Line Data and Key Metrics Changes - ASCENIV, the company's specialty immunoglobulin product, showed record utilization driven by strong prescriber adoption and sustained patient demand [6][10] - Product-level gross margins reached 63.7% during Q3 2025, excluding a plasma sale of $13.8 million, compared to 49.8% last year [11][12] Market Data and Key Metrics Changes - The company anticipates improved ASCENIV reimbursement access beginning in 2026, with payer negotiations progressing positively [6][10] - A retrospective cohort analysis indicated a significant reduction in infection rates for patients switching from standard IG therapy to ASCENIV, with a reduction of over 50% [7][26] Company Strategy and Development Direction - The company aims to expand ASCENIV access and utilization, scale yield-enhanced production, and drive continued margin expansion [10][19] - The SG001 program is progressing, with potential to address significant unmet medical needs and expected to contribute to long-term revenue growth [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $1.1 billion in annual revenue by 2029, supported by yield-enhancement efficiencies and expanding ASCENIV demand [14][15] - The company is optimistic about the future, citing a strong balance sheet and disciplined capital allocation strategy [19][10] Other Important Information - The FDA's release of yield-enhanced production batches is expected to improve gross margins starting in Q4 2025 [8][11] - The company maintains an undrawn $225 million revolving credit facility, providing flexibility for growth initiatives [10][14] Q&A Session Summary Question: Can you provide details on the publication of ASCENIV data? - Management confirmed plans for a peer-reviewed publication early in 2026, highlighting significant infection rate reductions with ASCENIV compared to standard IG therapy [24][26] Question: What is the expected growth curve for ASCENIV demand? - Management anticipates strong double-digit growth for ASCENIV, supported by ongoing data publication and payer negotiations [29][31] Question: What factors contributed to raising revenue guidance for 2026? - Confidence in revenue guidance was based on record product pull-through and increased availability of ASCENIV [35][40] Question: How will the FDA lot release impact gross margins? - Management expects gross margins to expand significantly in Q4 2025 and into 2026, potentially exceeding 70% [52][51] Question: What is the status of payer negotiations for ASCENIV? - Ongoing positive negotiations with payers are expected to improve access without significantly impacting gross margins [54][56] Question: How many physicians or centers are currently using ASCENIV? - Approximately 100 physicians are currently prescribing ASCENIV, with expectations for significant growth in the number of prescribers [59][61]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $134.2 million, reflecting a 10% increase quarter-over-quarter and a 12% increase year-over-year [6][12] - GAAP net income reached $36.4 million, up 6% quarter-over-quarter and 1% year-over-year [6][12] - Adjusted EBITDA grew to $58.7 million, representing a 16% quarter-over-quarter increase and a 29% year-over-year increase [6][12] - Gross margins expanded to approximately 56.3%, compared to 49.8% in the previous year [12] Business Line Data and Key Metrics Changes - ASCENIV, the company's specialty immunoglobulin product, showed record utilization driven by strong prescriber adoption and sustained patient demand [6][9] - Product-level gross margins reached 63.7% during Q3 2025, excluding a plasma sale of $13.8 million [12][13] Market Data and Key Metrics Changes - The company anticipates improved ASCENIV reimbursement access beginning in 2026 for select payers where restrictions previously existed [7] - A retrospective cohort analysis showed a statistically significant reduction in infection rates for patients transitioning from standard immune globulin therapy to ASCENIV, with a reduction of over 50% [7][26] Company Strategy and Development Direction - The company aims to expand ASCENIV access and utilization, scale yield-enhanced production, and drive continued margin expansion [11][18] - The SG001 program is progressing, with potential to address significant unmet medical needs and represent a $300-$500 million annual revenue opportunity [10][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $1.1 billion in annual revenue by 2029, supported by yield-enhancement efficiencies and expanding ASCENIV demand [14][15] - The company maintains a strong balance sheet with an undrawn $225 million revolving credit facility, providing flexibility for growth [11][15] Other Important Information - The FDA's release of yield-enhanced production batches is expected to improve per-batch output by 20% or more, driving sustained gross margin expansion [9][12] - The company is actively negotiating with payers to improve access and is seeing positive trends in payer negotiations [56] Q&A Session Summary Question: Can you provide details on the publication of ASCENIV data? - Management confirmed plans for a peer-reviewed publication early in 2026, highlighting significant reductions in infections for patients switching to ASCENIV [26][27] Question: What is the expected growth curve for ASCENIV demand? - Management expects strong double-digit growth, supported by ongoing data publication and payer negotiations [31][32] Question: What factors contributed to raising revenue guidance? - Confidence stems from record product pull-through and increased availability of ASCENIV, leading to robust acceleration in growth [36][38] Question: How will the FDA lot release impact gross margins? - Management anticipates continued gross margin expansion, potentially exceeding 70% as yield-enhanced products flow through [52][53] Question: What is the status of payer negotiations? - Active discussions are ongoing, with positive trends in approvals and movement from restricted lists expected in early 2026 [56][57] Question: How many physicians or centers are currently using ASCENIV? - Approximately 300 clinical immunologists are targeted, with over 100 currently prescribing ASCENIV [60][61]

Core Insights - ADMA Biologics reported a total revenue of $134.2 million for Q3 2025, reflecting a 12% year-over-year increase, with GAAP net income of $36.4 million, a 1% increase from the previous year [1][10][11] - The company raised its FY 2025 total revenue guidance to at least $510 million and FY 2026 guidance to at least $630 million, indicating strong growth expectations [1][4][7] - The FDA lot release of yield-enhanced production batches is expected to drive gross margin expansion starting in Q4 2025 and continuing through 2026 [2][8] Financial Performance - Q3 2025 adjusted EBITDA reached $58.7 million, a 29% increase year-over-year, while adjusted net income was $38.9 million, an 8% increase [1][12][11] - Gross profit for Q3 2025 was $75.6 million, with a gross margin improvement to 56.3% from 49.8% in the prior year, driven by higher-margin immunoglobulin sales and operational efficiencies [11][10] - The company’s total revenue for the nine months ended September 30, 2025, was $371 million, compared to $308.9 million for the same period in 2024 [34] Business Updates - ASCENIV demonstrated record demand and utilization, with ongoing negotiations for enhanced reimbursement expected to support growth in 2026 [2][8] - Positive real-world health outcomes for ASCENIV were reported, showing a significant reduction in infection rates among patients transitioning from standard immunoglobulin therapy [8] - The company is advancing its SG-001 pipeline program, which targets Streptococcus pneumoniae, with potential for significant market opportunity [15] Guidance and Projections - FY 2025 adjusted EBITDA guidance is reaffirmed at $235 million, while FY 2026 adjusted EBITDA guidance is raised to more than $355 million [7][1] - The company projects total annual revenue to exceed $1.1 billion by FY 2029, supported by anticipated earnings growth and operational momentum [5][1] - Adjusted net income guidance for FY 2025 is revised to approximately $158 million due to a higher effective tax rate, while FY 2026 guidance is raised to more than $255 million [7][1]

Core Insights - Palisades Investment Partners has completely exited its position in ADMA Biologics, selling 398,647 shares for approximately $7.3 million, indicating a strategic shift in investment focus [1][2][7] Company Overview - ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapeutics aimed at treating immune deficiencies and infectious diseases [6][9] - The company reported a total revenue of $474.2 million and a net income of $208.9 million for the trailing twelve months (TTM) [4] Financial Performance - ADMA Biologics experienced a year-over-year revenue growth of 14%, reaching $122 million, alongside a 7% increase in GAAP net income [8] - The stock price of ADMA Biologics closed at $15.48, reflecting a 5% decline over the past year, which is significantly lower than the S&P 500's 19% gain during the same period [3][4] Investment Strategy - Palisades' exit from ADMA Biologics highlights its adherence to a small-cap momentum strategy, where investments are sold when financial or operational momentum appears to stall [7][10] - The fund's decision to liquidate its position, despite ADMA's revenue and earnings growth, suggests a cautious outlook on the stock's future appreciation potential [10]

Core Insights - Adma Biologics reported Q2 2025 earnings with total GAAP revenue of $122.0 million, exceeding analyst expectations, and a GAAP EPS of $0.14, reflecting a year-over-year growth of 7.7% [1][2][5] Financial Performance - Revenue increased by 14.0% year-over-year from $107.2 million in Q2 2024 to $122.0 million in Q2 2025, driven by strong demand for ASCENIV® [2][5] - Adjusted EBITDA reached $50.8 million, marking a 14.2% increase from Q2 2024, while adjusted net income rose to $36.0 million, up 12.3% from $32.1 million [2][7] - Gross margin improved to 55.1%, up from 53.6% in Q2 2024, attributed to higher-margin immunoglobulin sales and operational efficiencies [2][6] Operational Developments - The company initiated commercial yield enhancement in manufacturing, with early production runs showing over a 20% increase in finished IG output, which is expected to significantly impact future revenue and profit [6][10] - Strategic investments included acquiring additional manufacturing space to expand capacity by up to 30% and completing a $300 million debt refinancing to lower borrowing costs [8][10] Product and Pipeline Insights - ASCENIV and BIVIGAM therapies continued to see robust demand, with ASCENIV utilization reaching new highs [9] - The development of SG-001, a candidate hyperimmune globulin for pneumococcal infections, showed promising results in animal studies, with potential peak annual revenue estimated between $300 million and $500 million [9] Future Outlook - Management reaffirmed revenue guidance of over $500 million for fiscal 2025 and more than $625 million for 2026, with total annual revenue expected to exceed $1.1 billion before 2030 [10] - The current guidance does not fully account for the impact of the FDA-approved yield enhancement or new pipeline products, indicating further growth potential [10][11]

Core Insights - ADMA Biologics reported a total revenue of $122.0 million for Q2 2025, reflecting a 14% year-over-year increase, and a 29% increase when excluding a prior-year non-recurring item [1][7] - The company achieved a GAAP net income of $34.2 million, a 7% increase year-over-year, and an adjusted net income of $36.0 million, representing an 85% increase when excluding the prior-year non-recurring item [1][9] - Adjusted EBITDA rose to $50.8 million, marking a 59% year-over-year increase after adjusting for the prior-year Medicaid rebate accrual benefit [1][10] - ADMA initiated commercial-scale manufacturing with an FDA-approved yield enhancement process, resulting in a 20%+ increase in finished immunoglobulin (IG) output [1][2] - The company secured a $300 million syndicated debt refinancing led by J.P. Morgan, which significantly lowers borrowing costs and enhances strategic optionality [1][3] - ADMA expanded its production operations by acquiring a new facility in Boca Raton, which could increase cGMP manufacturing space by up to 30% at peak [1][6] - The company reaffirmed its financial guidance for FY 2025 and 2026, projecting total revenue to exceed $500 million and $625 million, respectively [4][6] Financial Performance - Total revenue for Q2 2025 was $122.0 million, up from $107.2 million in Q2 2024, driven by the adoption of ASCENIV [7] - Gross profit increased to $67.2 million, with gross margin improving to 55.1% from 53.6% in the prior year [8] - The company reported a net income of $34.2 million compared to $32.1 million in Q2 2024, primarily due to higher operating income and lower interest expenses [9] - Adjusted EBITDA for the quarter was $50.8 million, up from $44.5 million in the same period of 2024 [10] Strategic Developments - The FDA-approved yield enhancement process is expected to drive gross margin expansion and support revenue growth [2][4] - ASCENIV utilization reached new highs, indicating strong demand and positioning the company to meet or exceed financial projections [3] - The acquisition of a new facility is expected to enhance operational efficiencies and support future capacity expansion [6][12] - ADMA repurchased approximately $15 million of common stock during Q2 2025, reflecting confidence in the company's long-term value creation potential [3][6]

Core Viewpoint - ADMA Biologics, Inc. will report its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results and other company updates [1]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM for primary humoral immunodeficiency, and NABI-HB for enhanced immunity against hepatitis B [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].